REVIEW 1 cited by
A Diagnostic Model for Acute Lymphoblastic Leukemia Using Metaheuristics and Deep Learning Methods
Not yet reviewed by Pith; the record is open.
This paper has not been read by Pith yet. Machine review is queued; the pith claim, tier, and objections will appear here once it completes.
SPECIMEN: schema-true, not a live event
T0 review · schema-true
One-sentence machine reading of the paper's core claim.
pith:XXXXXXXX · record.json · timestamp
read the original abstract
Acute lymphoblastic leukemia (ALL) severity is determined by the presence and ratios of blast cells (abnormal white blood cells) in both bone marrow and peripheral blood. Manual diagnosis of this disease is a tedious and time-consuming operation, making it difficult for professionals to accurately examine blast cell characteristics. To address this difficulty, researchers use deep learning and machine learning. In this paper, a ResNet-based feature extractor is utilized to detect ALL, along with a variety of feature selectors and classifiers. To get the best results, a variety of transfer learning models, including the Resnet, VGG, EfficientNet, and DensNet families, are used as deep feature extractors. Following extraction, different feature selectors are used, including Genetic algorithm, PCA, ANOVA, Random Forest, Univariate, Mutual information, Lasso, XGB, Variance, and Binary ant colony. After feature qualification, a variety of classifiers are used, with MLP outperforming the others. The recommended technique is used to categorize ALL and HEM in the selected dataset which is C-NMC 2019. This technique got an impressive 90.71% accuracy and 95.76% sensitivity for the relevant classifications, and its metrics on this dataset outperformed others.
Forward citations
Cited by 1 Pith paper
-
Acute Lymphoblastic Leukemia Diagnosis Employing YOLOv11, YOLOv8, ResNet50, and Inception-ResNet-v2 Deep Learning Models
A benchmark of four pretrained deep learning models for binary ALL classification reports 99.7% accuracy, but the paper's stage and hematogone detection claims are artifacts of label merging.
Discussion (0). Continue with ORCID to comment.